Global Myelodysplastic Syndrome (MDS) Drugs Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Myelodysplastic syndrome is caused by mutation of one or more genes that control development of blood cells. It is one of the most common malignant hematological diseases that affects five out of every 100,000 people in U.S. annually. An estimated 60,000 people in U.S. live with MDS, and approximately 10,000-15,000 new cases are reported each year. Patients may present with clinical manifestations such as thrombocytopenia, neutropenia, and anemia. Exposure to chemicals (such as pesticides, tobacco, and benzene) and heavy metals (such as mercury and lead) may trigger disease onset.
According to our (Global Info Research) latest study, the global Myelodysplastic Syndrome (MDS) Drugs market size was valued at USD 1496.4 million in 2022 and is forecast to a readjusted size of USD 2170.3 million by 2029 with a CAGR of 5.5% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
In recent years, demand for hypomethylating agents has been at a high due to approval and adoption of Vidaza and Dacogen. A strong pipeline including Aranesp is expected to boost market growth in the near future. Easy availability of and access to novel treatments in major countries provides strong commercial opportunities to the market.
This report is a detailed and comprehensive analysis for global Myelodysplastic Syndrome (MDS) Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Myelodysplastic Syndrome (MDS) Drugs market size and forecasts, in consumption value ($ Million), 2018-2029
Global Myelodysplastic Syndrome (MDS) Drugs market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Myelodysplastic Syndrome (MDS) Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Myelodysplastic Syndrome (MDS) Drugs market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Myelodysplastic Syndrome (MDS) Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Myelodysplastic Syndrome (MDS) Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Celgene, Amgen, Otsuka and Takeda, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Myelodysplastic Syndrome (MDS) Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
    Hypomethylating Agents
    Immunomodulatory Drugs
    Anti-anemics
Market segment by Application
    Original
    Generics
Market segment by players, this report covers
    Celgene
    Amgen
    Otsuka
    Takeda
Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Myelodysplastic Syndrome (MDS) Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Myelodysplastic Syndrome (MDS) Drugs, with revenue, gross margin and global market share of Myelodysplastic Syndrome (MDS) Drugs from 2018 to 2023.
Chapter 3, the Myelodysplastic Syndrome (MDS) Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Myelodysplastic Syndrome (MDS) Drugs market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Myelodysplastic Syndrome (MDS) Drugs.
Chapter 13, to describe Myelodysplastic Syndrome (MDS) Drugs research findings and conclusion.